Activating therapeutic

Treating disease with
Bioactive Antibody drugs

Controlling cellular behaviors
to treat disease

First focus: controlling GPCRs
(G-protein coupled receptors)

GPCRs regulate biology

G-protein coupled receptors (GPCRs) are membrane proteins that make cells respond to chemical signals like hormones.

Controlling GPCRs with drugs can treat diseases

Tuning GPCR activities up or down can harness our body's cellular activities to treat diseases. That's why 30% of all approved drugs target GPCRs.

Most GPCRs remain uncontrollable by drugs

Over 200 of the 400 potentially druggable GPCRs remain undrugged. Many control important disease-treating biological processes, or can cause disease if dysfunctional.

Small molecule drugs are failing

Off-target toxicity
Small molecules often have off-target activity for structurally similar GPCRs, leading to side effects.

Metabolic toxicity
Small molecules can also be processed by the body to yield toxic metabolites.

Difficult to drug targets
Bioactive small molecules often cannot be found for  some promising GPCRs, such as targets that normally respond to large protein signals like chemokines.

Current antibody drugs are limited

Naturally strong binders that inactivate
Nature evolved antibodies as our body's own drugs to selectively and potently inactivate pathogens.

Proven drugs, but rare for GPCRs
7 of the top 10-selling drugs are engineered antibodies.
However, out of 100 antibody drugs, only 2 target GPCRs.

Antibody drugs for GPCRs limited to blockers
It's hard enough finding a GPCR blocker. It's even harder to bind a GPCR in just the right way to activate it.

Of 100 approved antibody drugs, there is not a single antibody activator for a GPCR.

We expand the therapeutic reach of antibody drugs

We find Bioactive Antibodies that are activators and modulators, as well as negative regulators.

Abalone Bio's combines engineered living cells and data-driven computation to identify antibodies that functionally modulate the GPCR target -  including activators.

  • Platform compatible with VHH, scFvs, Fabs
  • Activate small AND large molecule receptors
  • Discover allosteric modulators and antagonists too
  • Cleaner than crosstalk-filled mammalian cell assays
  • Combines experimental and computational

Bioactive Antibodies access the full therapeutic potential of antibody drugs for GPCRs.

Supported by grants and investments from

NSF logo
NIH logo
YCombinator logo
Pioneer Fund logo
Harmonix partners logo
box 1 logo